Clinical Trial Detail

NCT ID NCT03437070
Title Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements no
Sponsors Marilyn Huang
Indications

leiomyosarcoma

Therapies

Doxorubicin + Olaratumab + Trabectidin

Age Groups: adult senior

No variant requirements are available.